← Back to Search

IBPS-Guided Ultrafiltration for Kidney Failure

N/A
Recruiting
Led By Peter Noel Van Buren, MD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Hemodialysis patient
Be older than 18 years old
Must not have
Documented antihypertensive medication non-adherence
Routine intradialytic clonidine use
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new strategy for fluid removal during dialysis that is based on a patient's recent blood pressure patterns. The goal is to compare this new strategy to standard care and assess the outcomes of overall blood pressure change between dialysis treatments.

Who is the study for?
This trial is for Veterans with kidney failure who are on hemodialysis and have high blood pressure before or after treatments. They must not be pregnant, have a pacemaker, metallic implants, or severe low blood pressure issues. Also excluded are those new to dialysis, using certain blood pressure medications during dialysis, or non-adherent to antihypertensive meds.
What is being tested?
The study tests a new method of removing fluid during dialysis based on patients' recent blood pressure trends compared to standard care. It aims to see if this can manage overall blood pressure better and reduce dangerous drops in blood pressure that occur during the treatment process.
What are the potential side effects?
Potential side effects may include fluctuations in blood pressure levels which could lead to episodes of very low or unstable pressures during and after the dialysis sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am on hemodialysis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not consistently taken my blood pressure medication as prescribed.
Select...
I regularly use clonidine during dialysis.
Select...
I have an amputation, a cardiac device, or a metallic implant.
Select...
I regularly take midodrine during dialysis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ambulatory Systolic Blood Pressure
Secondary study objectives
Association Between intradialytic blood pressure slope with systolic and diastolic dysfunction
Extracellular Volume
Intradialytic Hypotension
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: IBPS (Intradialytic Blood Pressure Slope) ArmExperimental Treatment1 Intervention
IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.
Group II: ControlActive Control1 Intervention
Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,663 Previous Clinical Trials
3,427,219 Total Patients Enrolled
Peter Noel Van Buren, MDPrincipal InvestigatorVA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

Media Library

IBPS-Guided Ultrafiltration Clinical Trial Eligibility Overview. Trial Name: NCT04163614 — N/A
High Blood Pressure Research Study Groups: Control, IBPS (Intradialytic Blood Pressure Slope) Arm
High Blood Pressure Clinical Trial 2023: IBPS-Guided Ultrafiltration Highlights & Side Effects. Trial Name: NCT04163614 — N/A
IBPS-Guided Ultrafiltration 2023 Treatment Timeline for Medical Study. Trial Name: NCT04163614 — N/A
~9 spots leftby Jul 2025